4220-10-4

Usage

Uses

Used in Pharmaceutical Industry:
MPTP is used as an analgesic agent for its potential pain-relieving properties, as it has shown effectiveness in animal models. It is also being investigated for its potential role in treating addiction and substance abuse disorders.
However, MPTP has a high potential for abuse and addiction, leading to its tightly regulated use in many countries. Its neurotoxic effects, particularly in the dopaminergic system, have raised concerns about its safety and have prompted further research into its potential role in neurodegenerative diseases such as Parkinson's disease.

Upstream product

• 57-42-1 pethidine 
• 3627-62-1 1-methyl-4-phenyl-piperidine-4-carbonitrile 
• 40481-13-8 4-phenyl-4-cyanopiperidine 
• 71258-18-9 1-benzyl-4-phenyl-piperidine-4-carbonitrile; hydrochloride 

Downstream Products

• 102309-82-0 1-methyl-4-phenyl-4-(2-piperidino-ethoxymethyl)-piperidine 
• 117878-08-7 4-[2-(1,1-dimethyl-4-phenyl-piperidinium-4-ylmethoxy)-ethyl]-4-methyl-morpholinium; diiodide 
• 111416-94-5 1,1-dimethyl-4-phenyl-4-(2-trimethylammonio-ethoxymethyl)-piperidinium; diiodide 

Relevant academic research and scientific papers

Muscarinic acetylcholine receptor binding affinities of pethidine analogs

A series of pethidine analogs were synthesized and their affinities for the [3H]N-methyl-scopolamine (NMS) binding site on muscarinic acetylcholine receptors (mAChRs) were determined using M1, M3 or M5 human mAChRs expressed by Chinese hamster ovary (CHO) cell membranes. Compound 6b showed the highest binding affinities at M1, M3 and M5 mAChRs (Ki = 0.67, 0.37, and 0.38 μM, respectively).

NAPHTHYL ETHER COMPOUNDS AND THEIR USE

Compounds having the following structure wherein R1, R2, R3, R4, R5, R6, R7 m and n are as defined in the specification, in vivo-hydrolysable precursors thereof, pharmaceutically-acceptable salts thereof, the use in therapy and pharmaceutical compositions and methods of treatment using the same.

4-phenylpiperidine compounds and their use

Piperidine compounds having the formula STR1 wherein R1 is hydrogen, (C1-6 -alkoxyaryl)alkyl, diphenylmethozy-C1-6 -alkyl, C1-8 -alkyl, C4-10 -cycloalkylalkyl, phenoxy-C1-8 -alkyl, or C1-6 -alkoxy-C1-6 -alkyl; and R is STR2 or CH=NOR' wherein R' is C1-6 -alkyl, C3-7 -cycloalkyl, C1-6 -alkoxy-C1-6 -alkyl, aryl-C0-6 -alkyl, which may optionally be substituted with one or more halogen and (1-5 -alkoxy, thienyl, or C4-7 -cycloalkylalkyl. The novel compounds are useful for the treatment of pain conditions and as neuroleptics.